Table I.
Characteristics of the studies included in the meta-analysis investigating the use of anti-TNF agents in patients with SpA or AS.
| Anti-TNF group | Control group | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First author, year | Type of disease | Duration (weeks) | Treatment | P (n) | I (n) | SI (n) | TB (n) | Treatment | P (n) | I (n) | SI (n) | TB (n) | (Refs.) |
| Dougados et al, 2014 | axSpA | 12 | ETA 50 mg Qw | 106 | 11 | 0 | 0 | PBO | 109 | 10 | 1 | 0 | (20) |
| Braun et al, 2010 | AS | 16 | ETA 50 mg Qw | 379 | 43 | 0 | 0 | SSZ | 187 | 26 | 0 | 0 | (21) |
| Dougados et al, 2010 | SpA | 12 | ETA 50 mg Qw | 12 | 5 | 1 | 0 | PBO | 12 | 1 | 0 | 0 | (22) |
| van der Heijde et al, 2006 | AS | 12 | ETA 50 mg Qw or 25 mg Biw | 305 | 68 | 2 | 0 | PBO | 51 | 12 | 0 | 0 | (15) |
| Mease et al, 2004 | PsA | 24 | ETA 25 mg Biw | 101 | 33 | 0 | 0 | PBO | 104 | 39 | 1 | 0 | (23) |
| Calin et al, 2004 | AS | 12 | ETA 25 mg Biw | 45 | 0 | 0 | 0 | PBO | 39 | 0 | 0 | 0 | (24) |
| Davis et al, 2003 | AS | 24 | ETA 25 mg Biw | 138 | 44 | 2 | 0 | PBO | 139 | 43 | 1 | 0 | (25) |
| Brandt et al, 2003 | AS | 24 | ETA 25 mg Biw | 14 | 6 | 0 | 0 | PBO | 16 | 6 | 0 | 0 | (26) |
| Gorman, 2002 | AS | 16 | ETA 25 mg Biw | 20 | 12 | 2 | 0 | PBO | 20 | 12 | 0 | 0 | (27) |
| Sieper et al, 2013 | axSpA | 24 | IFX 5 mg/kg+NPX 0, 2, 6, 12, 18, 24 w | 105 | 27 | 1 | 1 | PBO + NPX | 52 | 9 | 0 | 0 | (28) |
| Baranauskaite et al, 2011 | PsA | 16 | IFX 5 mg/kg+MTX 0, 2, 6, 14 w | 57 | 4 | 2 | 1 | MTX | 54 | 0 | 0 | 0 | (29) |
| Marzo-Ortega et al, 2005 | AS | 30 | IFX 5 mg/kg+MTX 0, 2, 6, 14, 22 w | 28 | 6 | 0 | 0 | PBO + MTX | 14 | 2 | 0 | 0 | (30) |
| van der Heijde et al, 2004 | AS | 24 | IFX 5 mg/kg 0, 2, 6, 12, 18 w | 201 | 86 | 2 | 0 | PBO | 78 | 27 | 0 | 0 | (31) |
| Antoni et al, 2004 | PsA | 16 | IFX 5 mg/kg 0, 2, 6, 14 w | 52 | 9 | 1 | 0 | PBO | 51 | 16 | 1 | 0 | (32) |
| Van Den Bosch et al, 2002 | SpA | 12 | IFX 5 mg/kg 0, 2, 6 w | 20 | 9 | 1 | 1 | PBO | 20 | 6 | 0 | 0 | (33) |
| Braun et al, 2002 | AS | 12 | IFX 5 mg/kg 0, 2, 6 w | 34 | 12 | 1 | 1 | PBO | 35 | 18 | 0 | 0 | (34) |
| Mease et al, 2015 | npSpA | 12 | ADA 40 mg Eow | 84 | 18 | 0 | 0 | PBO | 81 | 23 | 0 | 0 | (2) |
| Huang et al, 2013 | AS | 12 | ADA 40 mg Eow | 229 | 25 | 1 | 0 | PBO | 115 | 12 | 0 | 0 | (35) |
| Sieper et al, 2012 | axSpA | 12 | ADA 40 mg Eow | 91 | 28 | 0 | 0 | PBO | 94 | 28 | 0 | 0 | (36) |
| Paramarta et al, 2012 | SpA | 12 | ADA 40 mg Eow | 20 | 4 | 0 | 0 | PBO | 20 | 8 | 1 | 0 | (37) |
| Horneff et al, 2012 | Jo-AS | 12 | ADA 40 mg Eow | 17 | 6 | 2 | 0 | PBO | 15 | 6 | 1 | 0 | (38) |
| van der Heijde et al, 2006 | AS | 24 | ADA 40 mg Eow | 208 | 66 | 0 | 0 | PBO | 107 | 23 | 1 | 0 | (39) |
| Mease et al, 2005 | PsA | 24 | ADA 40 mg Eow | 151 | 36 | 1 | 0 | PBO | 162 | 41 | 2 | 0 | (40) |
| Sieper et al, 2015 | axSpA | 16 | GLM 50 mg Q4w | 97 | 0 | 0 | 0 | PBO | 100 | 0 | 0 | 0 | (41) |
| Mok et al, 2015 | axSpA | 48 | GLM 50 mg Q4w | 20 | 6 | 0 | 0 | PAM | 10 | 1 | 0 | 0 | (42) |
ETA, etanercept; IFX, infliximab; ADA, adalimumab; GLM, golimumab; PBO, placebo; MTX, methotrexate; NPX, naproxen; SSZ, sulfasalazine; PAM, pamidronate; P, participant; I, infection; SI, serious infection; TB, tuberculosis; n, number; w, week; Qw, once weekly; Biw, twice weekly; Eow, every other week; Q4w, every 4 weeks; SpA, spondyloarthritis; AS, ankylosing spondylitis; axSpA, axial SpA; PsA, psoriatic arthritis; npSpA, nonpsoriatic peripheral SpA; Jo-AS, juvenile onset AS.